Document:

<PAGE>

                                                                    EXHIBIT 10.3

                            CONFIDENTIAL TREATMENT

                        DEVELOPMENT AND SUPPLY AGREEMENT

     This Agreement is made this third day of April, 2000 ("Effective Date") by
and between Cubist Pharmaceuticals, Inc., having a principal place of business
at 24 Emily Street, Cambridge, Massachusetts 02139 (hereinafter referred to as
"Cubist") and Abbott Laboratories, having a principal place of business at 100
Abbott Park Road, Abbott Park, Illinois 60064-3500 (U.S.A.) (hereinafter
referred to as "Abbott").

                                   WITNESSETH:

     WHEREAS, Cubist owns rights to the compound daptomycin, an injectable
antibiotic drug, and wishes to develop and market the drug in a standard flip
top vial for the treatment of serious gram positive infections;

     WHEREAS, Cubist and Abbott desire that Abbott assist Cubist in the
development of daptomycin as a parenteral formulation;

     WHEREAS, after Cubist has received an approved NDA from the U.S. Food
and Drug Administration ("FDA") and/or corresponding new drug approvals in
selected international markets, the parties desire that Abbott manufacture
[   ]*, daptomycin as a parenteral formulation.

     NOW, THEREFORE, in consideration of the premises and the mutual promises
and agreements contained herein, Cubist and Abbott agree as follows:

                             ARTICLE 1. DEFINITIONS
                             ----------------------

     The following words and phrases when used herein with capital letters shall
have the meanings set forth or referenced below:

     1.1 "Bulk Drug" shall mean the Drug in bulk form that Cubist or its Bulk
Drug suppliers shall deliver to Abbott for incorporation into Product and
meeting the applicable Bulk Drug Specifications.

     1.2 "Bulk Drug Specifications" shall mean the detailed description and
parameters of Bulk Drug set forth on Exhibit 1.2.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -2-

     1.3 "Confidential Information" shall mean all information disclosed
hereunder in writing and identified as being confidential or, if disclosed
orally, visually or through some other media, is identified as confidential at
the time of disclosure and is reduced to writing within thirty (30) days of
disclosure and identified as being confidential, except any portion thereof
which:

     a. is known to the recipient, as evidenced by the receiving party's written
        records, before receipt thereof under this Agreement;

     b. is disclosed in good faith to the recipient after acceptance of this
        Agreement by a third person lawfully in possession of such information
        and not under an obligation of nondisclosure;

     c. is or becomes part of the public domain through no fault of the
        recipient;

     d. is developed by or for the recipient independently of information
        disclosed hereunder as evidenced by the recipient's written records or
        other competent evidence; or

     e. is required by law to be disclosed; provided notice of such disclosure
        is provided to the disclosing party prior to such disclosure.

     1.4 "Contract Year" shall mean the twelve-month period commencing on the
first day of the month after the month of Cubist's first bona fide sale of
Product to a non-affiliate customer after Product has received an approved NDA
from the FDA and/or a corresponding government marketing approval in an
international market.

     1.5 "Drug" shall mean the human antibiotic pharmaceutical that Cubist
refers to as daptomycin and described in Exhibit 1.5.

     1.6 "NDA" shall mean the daptomycin New Drug Application filed with the FDA
to obtain regulatory approval in the US.

     1.7 "Product" shall mean the Drug in final dosage form, packaged in a
standard flip top vial, meeting the Product Specifications.

     1.8 "Product Specifications" shall mean those product, labeling and
performance specifications for Product filed with the FDA or other appropriate
regulatory authorities, including Product formula and materials required for the
manufacture of the Product that is to be purchased and

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -3-

supplied under this Agreement, as such are set forth on Exhibit 1.8, which
specifications may be amended from time to time by the written agreement of the
parties.

     1.9 "Term" shall mean the period commencing on the Effective Date and
ending at the end of the fifth Contract Year, unless this Agreement is sooner
terminated in accordance with Paragraph 11.2 or 11.3 or extended in accordance
with Paragraph 11.1.

                     ARTICLE 2. PRODUCT DEVELOPMENT PROJECT
                     --------------------------------------

     2.1 GENERAL. Promptly following the Effective Date, the parties shall
undertake a product development project ("Project") consisting of the
development activities outlined in Articles 3 and 4 hereof. The Project will be
conducted in accordance with the Project Timetable attached hereto as Exhibit
2.1.

     2.2 REASONABLE EFFORTS. Each party shall use its reasonable efforts to
complete successfully the Project in accordance with the Project Timetable
specified in Exhibit 2.1. However, the parties agree and understand that neither
party hereto guarantees that the Project will be successful, nor warrants or
guarantees that a marketable Product will result from the Project. In the event
that Abbott's Project Development Responsibilities, described in Section 3,
prior to regulatory submission are not completed [ ]* after the date specified
in Exhibit 2.1 (after taking into account any mutually agreed upon date
adjustments and assuming that Cubist has fulfilled its Project Development
Responsibilities), the parties shall meet and discuss appropriate remedies. If
the parties are unable to agree upon an allocation of responsibility, damages
and payment terms, the matter shall be resolved by Alternative Dispute
Resolution ("ADR") in accordance with the procedure set forth in Exhibit 13.4.

                ARTICLE 3. ABBOTT'S DEVELOPMENT RESPONSIBILITIES
                ------------------------------------------------

     3.1 ABBOTT'S RESPONSIBILITIES. The objective of the Project shall be for
Abbott to assist in the development of the Product and to assist Cubist in
obtaining an approved NDA (and/or foreign equivalents) covering the Product.
Abbott shall then manufacture and deliver Product to Cubist for sale by Cubist
as a human pharmaceutical product, as herein provided. Abbott shall have the
following responsibilities, as required:

     a. Identify compatible components for use in manufacturing the Drug.

<PAGE>
                                      -4-

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

     b. Manufacture clinical supplies, stability supplies, NDA consistency
        batches and process validation batches of Product in accordance FDA and
        European Union ("EU") guidelines for current Good Manufacturing
        Practices ("cGMPs") and pursuant to protocols that the parties shall
        agree to mutually.

     c. [   ]*

     d. Prepare suitable manufacturing instructions and manufacturing controls
        for inclusion in regulatory submissions.

     e. Provide appropriate regulatory agencies with letters of authorization
        referencing Abbott's Drug Master File ("DMF"). The DMF shall contain
        general operational information about Abbott's manufacturing including
        but not limited to microbiological data, process validation data,
        batch documents and other data required to support regulatory
        submissions. In addition, provide Cubist with specific Product related
        Chemistry, Manufacturing and Controls ("CMC") documentation as
        required by regulatory guidelines to support the US and EU regulatory
        filings of the Product, provided that Abbott shall not be required to
        prepare more than one set of CMC documentation in connection with EU
        regulatory filings.

     f. Provide Cubist and appropriate regulatory agencies with letters of
        reference to Abbott's applicable DMFs needed to support Cubist
        worldwide regulatory submissions related to Product and assist Cubist
        in responding to questions from government regulatory agencies
        concerning the Product.

     g. [   ]*

     h. Permit Cubist to conduct all necessary cGMP and quality assurance
        reviews of Abbott documentation, including review and receipt of
        copies of Abbott manufacturing work orders.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -5-

     i. Permit Cubist to conduct all necessary cGMP and quality assurance
        reviews of Abbott facilities and operations, subject to the provisions
        of Paragraph 8.4.8.

     j. Provide Cubist with acceptable environmental impact statements for
        inclusion with regulatory submissions.

     k. Assist Cubist in the development of instructions for use, which will be
        submitted as labeling in regulatory submissions relating to Product.

     l. Provide Cubist with appropriate manufacturing documentation for
        regulatory submissions. Provide safe record retention for the period
        required by regulatory authorities.

     m. Provide Cubist with development reports and stability reports to support
        regulatory filings.

     n. [   ]*

     o. Maintain adequate samples of the marketed Product and provide samples as
        required by third party analytical laboratories and contracted by Cubist
        to assist in commercial Product release and stability studies.

                ARTICLE 4. CUBIST'S DEVELOPMENT RESPONSIBILITIES
                ------------------------------------------------

4.1 CUBIST'S RESPONSIBILITIES. Cubist shall have the following development
responsibilities:

     a. Optimize Product information transfer for formulation and Project
        approaches in consultation with Abbott.

     b. Provide approved Bulk Drug from Cubist's Bulk Drug suppliers, with
        certificates of analysis, at no cost to Abbott, for formulation
        studies, stability supplies, manufacturing studies, and other needs as
        required by Abbott for execution of its responsibilities under this
        Agreement.

<PAGE>
                                      -6-

     c. Provide Abbott with reference and assay standards for Bulk Drug and any
        other proprietary assay standards and certificates of analysis as may
        be required to perform quality control testing, including all
        necessary reference standards.

     d. Develop and provide to Abbott validated analytical test methods for Bulk
        Drug and Product to be used for regulatory submissions, as well as for
        use in manufacture of Product. Validation which is determined to be
        required beyond that provided by Cubist, will be mutually agreed upon
        and resolved with Abbott to assure both validation and regulatory
        compliance.

     e. Provide all compendial specifications and testing instructions for Bulk
        Drug, if such specifications are available.

     f. Provide Abbott with technical data on Bulk Drug that includes, but is
        not limited to, the following: 1) material safety data sheets with
        environmental and safety information, and 2) additional detailed data,
        if necessary, to define potential hazards and establish employee
        exposure levels and equipment cleanability limits.

     g. Perform and be responsible for all clinical/efficacy studies necessary
        to obtain regulatory approval.

     h. Conduct all stability testing (including marketed Product stability
        testing), retain all samples required to conduct stability testing and
        compile data for regulatory submissions.

     i. Prepare and submit to appropriate government regulatory agencies
        submissions covering Product, respond to all questions from the
        regulatory agencies, take necessary steps to obtain marketing
        approvals and to maintain the approved regulatory submissions.

     j. Provide Abbott with copies of regulatory filings as necessary for Abbott
        to obtain regulatory pre-inspections.

     k. Conduct all other research and development and other work required to
        submit appropriate regulatory submissions and to obtain marketing
        approvals covering product.

<PAGE>
                                      -7-

               ARTICLE 5. PAYMENT FOR ABBOTT'S DEVELOPMENT EFFORTS
               ---------------------------------------------------

     5.1 MANUFACTURING IMPLEMENTATION AND DEVELOPMENT FEE. To reimburse Abbott
for its participation in the Project, Cubist shall pay to Abbott several,
non-refundable development fees in the form of milestone payments as described
in Paragraph 5.3.

     5.2 [ ]*.

     5.3 MILESTONE PAYMENTS. Cubist agrees to pay Abbott the following milestone
payments according to the Project Timetable described in Exhibit 2.1:

     a. [   ]*

     b. [   ]*

     c. [   ]*

     d. [   ]*

     e. [   ]*

     f. [   ]*

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -8-

     g. [   ]*

     5.4 CHANGES. If changes occur in the Project or Product Specifications, or
if technical difficulties require that Abbott perform either additional work or
repeat work, and the reasons for such work are not due to Abbott's fault or
negligence, Cubist shall pay Abbott's costs for such work, subject to Cubist's
prior approval which shall be requested using the procedure specified in this
Paragraph 5.4. Reimbursement for such additional work shall be at the rate of
[ ]* Dollars (US$[ ]*) per hour, plus out-of-pocket costs for reasonable travel
and substance, materials and supplies. Abbott shall provide Cubist with a new or
revised test protocol with cost estimates for such work and Cubist shall pay
Abbott within [ ]* of completion of such work. No changes to the Product
Specifications or the Project will be made without written approval of Cubist
and Abbott. Either party may request amendments to Product Specifications or the
Project. If a party wishes to make a change it shall notify the other party of
the requested change specifying the change with sufficient details to enable the
other party to evaluate the change (a "Change Request"). Within [ ]* following
the date of Abbott's receipt of a Cubist Change Request, Abbott shall deliver a
document that: (a) assesses the impact of the change on the total cost of the
Project, the Product and the Project Timetable, and (b) incorporates a
description of the requested change and its cost (a "Change Control Document").
Any Abbott Change Request shall include all information specified for a Change
Control Document said the procedure specified in the preceding sentence shall
apply to Cubist's review of same. If Cubist accepts the Change Control Document,
then the provisions of this Agreement shall be deemed amended to incorporate
such change in accordance with the Change Control Document. The price stated in
the Change Control Document shall be deemed an increase in the charges specified
in the then applicable Project and Project Timetable.

     5.5 [   ]*

     5.6 NDA STABILITY STUDIES. If Cubist requests, Abbott will consider having
performed or performing NDA stability studies for Cubist. If

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -9-

requested, Abbott shall provide an estimate of the time required and costs
associated with performing such stability studies.

     5.7 USER FEES. [ ]* shall pay any FDA (or foreign equivalent) user fees
which may become payable for Product.

                   ARTICLE 6. CLINICAL AND STABILITY SUPPLIES
                   ------------------------------------------

     6.1 STABILITY SUPPLIES. After Cubist selects its final Product formulation,
concentration and fill volume, and the parties mutually agree to the final
Product Specifications, Abbott shall provide to Cubist stability supplies
consisting of [ ]* lots of Product with each lot consisting of no more than [ ]*
units. If possible, Abbott shall manufacture all lots from different production
lots of Bulk Drug. Cubist and Abbott shall develop jointly and agree mutually to
the formulation, concentration, fill volume and the components for each lot.
Abbott currently estimates the cost of manufacturing stability lots of fewer
than [ ]* units to be [ ]* per lot. The per unit cost of Product manufactured in
connection with this Paragraph 6.1 for lots consisting of more than [ ]* units
is set forth on Exhibit 8.5.1. If Cubist and Abbott agree to split a master
batch such that the yield is less than [ ]* units @ [ ]* Product and less than
[ ]* units @ [ ]* Product, the aggregate cost will not exceed [ ]*.

     6.2 ADDITIONAL STABILITY/CLINICAL SUPPLIES. If Cubist, the FDA or any other
regulatory authority requires additional stability supplies or sample lots from
the Abbott manufacturing facility, other than those specified above, Cubist will
issue separate purchase order(s) for such supplies or lots consisting of
approximately [ ]* units. Abbott currently estimates the cost of manufacturing
stability lots of fewer than [ ]* units to be [ ]* per lot. The per unit cost of
Product manufactured in connection with this Paragraph 6.2 for lots consisting
of more than [ ]* units is set forth on Exhibit 8.5.1.

                   ARTICLE 7. CUBIST'S REGULATORY SUBMISSIONS
                   ------------------------------------------

     Abbott shall have the right to review those portions of Cubist's proposed
regulatory submissions relating to Abbott's packaging or manufacturing
procedures before the submissions are filed with appropriate regulatory
agencies. Abbott shall complete its review of any such submission within [ ]*
after receipt of such proposed regulatory submission. Abbott shall consult with
and advise Cubist in responding to questions from the regulatory agencies
regarding Cubist's submission(s) for Product. Abbott agrees that Cubist shall be
the sole owner of any regulatory submission filed pursuant to this Agreement.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -10-

                  ARTICLE 8. MANUFACTURE AND SUPPLY OF PRODUCT
                  --------------------------------------------

     8.1 PURCHASE AND SALE OF PRODUCT. Subject to the provisions of Paragraph
8.3 and during the Term of this Agreement, Abbott shall manufacture, sell and
deliver Product to Cubist and Cubist shall take delivery and purchase a minimum
of [ ]* percent ([ ]*%) of their worldwide requirements of Product per Contract
Year from Abbott according to the schedule outlined in Exhibit 8.1. Abbott shall
manufacture Product in accordance with the Product Specifications, as amended by
mutual agreement of the parties. The parties may alter from time to time the
Product Specifications by mutual written agreement without the necessity of
amending this Agreement.

     8.2 MINIMUM PURCHASE REQUIREMENT. Cubist covenants to purchase from Abbott
not less than [ ]* units of Product during the Term, with the intent that Cubist
purchase from Abbott not less than [ ]* Dollars (US$ [ ]* of Product in each of
the third, fourth and fifth Contract Years ("Minimum Purchase Requirement"). In
the event Cubist purchases less than the Minimum Purchase Requirement of Product
from Abbott in any of the third, fourth or fifth Contract Years, the parties
will elect that either (i) Abbott shall invoice Cubist for the difference
between the amount of Product purchased in such Contract Year and the Minimum
Purchase Requirement, and Cubist shall pay Abbott within [ ]* days after receipt
of Abbott's invoice, or (ii) the prices set forth on Exhibit 8.5.1 shall be
adjusted accordingly.

     8.3 GOVERNMENT APPROVALS. Notwithstanding any other provision of this
Agreement, Abbott shall have no obligation to manufacture, sell or deliver
Product to Cubist and Cubist shall have no obligation to purchase and take
delivery of Product for commercial purposes in a specific territory until Cubist
has obtained necessary government approvals required to manufacture and sell
Product in such territory. In the event a regulatory authority orders the
withdrawal of Product from any country, Cubist shall not be obligated to
purchase the Product or sell the Product in such country from the date of such
withdrawal and until Cubist is again authorized to sell Product in such country,
and Abbott shall not be obligated to supply the Product to Cubist for sale in
such country for such period. If such a withdrawal decision is final and not
appealable, this Agreement shall terminate with respect to such country.

     8.4 MANUFACTURE OF PRODUCT

     8.4.1 BULK DRUG SUPPLY. Abbott shall manufacture Product for Cubist from
Bulk Drug that Cubist supplies at no cost to Abbott and in quantities sufficient
to satisfy Abbott's gross manufacturing requirements of Product.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -11-

Cubist shall deliver Bulk Drug, F.O.B. Abbott's manufacturing plant, pursuant to
no-cost purchase orders that Abbott issues to Cubist. Cubist warrants to Abbott
that Bulk Drug supplied to Abbott hereunder shall meet the Bulk Drug
Specifications. Abbott agrees that Abbott's use of Bulk Drug received from
Cubist shall be limited to development contemplated by this Agreement and the
manufacture of Product for Cubist. Within [ ]* after Abbott receives each
shipment of Bulk Drug supplied by Cubist hereunder, Abbott shall (a) perform an
identification test on the Bulk Drug and confirm the shipment amount and, (b)
notify Cubist of any claim that any portion of that shipment failed the
identification test or the quantity was inaccurate. In the event of such claim,
Cubist shall have the right to confirm such findings at Abbott's manufacturing
location, and upon such confirmation, Cubist shall replace, at no cost to
Abbott, the portion of the Bulk Drug shipment which represented the short fall
amount (if quantity was at issue) or failed the identification test.

     8.4.2 BULK DRUG REPLACEMENT. If due to an intentionally wrongful act or any
negligent act or omission on Abbott's part in the examination of Bulk Drug
supplied by Cubist, and as a result thereof, the Product that Abbott
manufactures therewith fails to conform with the Product Specifications,
Abbott's sole liability in such case shall be limited to replacement of Product,
at no cost to Cubist, with conforming Product using Bulk Drug that Abbott
purchases from Cubist at Cubist's purchase cost/kg (as evidenced by Cubist's
invoices that Cubist provides by notice to Abbott from time to time). Abbott's
responsibilities (and associated costs) for replacing lost, damaged or otherwise
unusable Bulk Drug pursuant to this Subparagraph 8.4.2 shall in no event exceed
[ ]* Dollars (US$[ ]*) per batch. Notwithstanding the foregoing to the contrary,
this Subparagraph 8.4.2 shall not limit any liability of Abbott under
Subparagraph 8.8.4.

     8.4.3 BULK DRUG TITLE AND CONSUMPTION. Cubist shall retain title to the
Bulk Drug that it supplies to Abbott hereunder. Abbott shall assume all
responsibility and risk for the safekeeping, storage and handling of all
shipments of Bulk Drug delivered hereunder. In the event of loss or damage,
Cubist shall supply to Abbott Bulk Drug required for replacement at Cubist's
purchase cost/kg as evidenced by Cubist's invoices provided by notice to Abbott
from time to time. The consumption of Bulk Drug for the manufacture of Product
shall be in accordance with the maximum consumption factors that Abbott and
Cubist agree upon mutually in writing as promptly as practicable; where such
consumption factors are subject to change from time to time by mutual written
agreement of the parties. If during any [ ]* period, the consumption of Bulk
Drug to produce a given quantity of Product exceeds the maximum agreed upon
consumption factors for such quantity of Product, Abbott shall promptly
reimburse Cubist for the consumed excess at Cubist's

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -12-

purchase cost/kg as evidenced by Cubist's invoices that Cubist provides by
notice to Abbott from time to time. Abbott's responsibilities (and associated
costs) for reimbursing Cubist for excess consumption of Bulk Drug pursuant to
this Subparagraph 8.4.3 shall in no event exceed [ ]* Dollars (US$[ ]*) per
twelve (12) month period.

     8.4.4 NON-STANDARD EQUIPMENT COSTS. If non-standard, specialized equipment
is required to manufacture Product for Cubist, Cubist shall pay the cost of such
equipment, subject to Cubist's prior approval of such costs, which approval
shall not be unreasonably withheld Abbott shall advise Cubist of specialized
equipment required and the estimated cost(s) associated with the purchase and
installation of such equipment. Abbott shall bill Cubist for the associated
costs after Abbott installs the equipment. Cubist shall make payment to Abbott
no later than [ ]* after Cubist receives an invoice from Abbott. Title to the
equipment shall be in Abbott's name. If Abbott uses the specialized equipment
for manufacture of a product other than Product for Cubist, Abbott shall
promptly notify Cubist and purchase the equipment by paying Cubist the then
current book value of the equipment. This provision shall not apply to any
standard equipment normally used or required for the manufacture of Product or
for additional standard equipment required to increase production capacity or
efficiency at Abbott's manufacturing plant. Cubist purchased equipment will be
transferred to Cubist with title at the completion or termination of the
Project, provided that Abbott has not purchased such equipment from Cubist
pursuant to this Subparagraph 8.4.4. In general, no customized or specialized
equipment is expected.

     8.4.5 ACCESS TO DRUG MASTER FILES. Abbott shall manufacture Product that
conforms with Product Specifications. Abbott shall grant Cubist reference rights
to all DMFs necessary to support Cubist's applications for marketing
authorizations of Product. To effect this, Abbott shall execute Letters of
Authorization to regulatory authorities permitting such regulatory authorities
to consult Abbott's DMFs in their review of Cubist's Product marketing
authorizations. Abbott shall send copies of such Authorization Letters to
Cubist. Abbott shall update its DMFs annually and shall inform Cubist prior to
any modifications in order to permit Cubist to amend or supplement any affected
regulatory applications and files for Product.

     8.4.6 PRODUCT LABELING. Abbott shall label Product in accordance with label
copy that Cubist provides. Such copy may be modified from time to time by
agreement of the parties. Cubist shall reimburse Abbott for Abbott's actual
costs of making any label copy changes.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -13-

     8.4.7 QUALITY CONTROL. Abbott shall apply its quality control procedures
and in-plant quality control checks on the manufacture of Product for Cubist in
the same manner as Abbott applies such procedures and checks to products
(bearing like qualities to the Drug) that Abbott manufactures and sells for its
own account. In addition, Abbott will test and release Product in accordance
with the test methods described in Exhibit 8.4.7 to ensure that Product conforms
to the Product Specifications. The parties may change the test methods from time
to time and by mutual agreement. Abbott shall provide or cause to be provided,
for each lot of Product purchased pursuant to this Agreement, a certificate of
manufacturing compliance, containing the types of information which shall have
been approved by Cubist, which will certify that the lot of Product was
manufactured in accordance with the Product Specifications and cGMPs, as the
same may be amended from time to time.

     8.4.8 AUDITS. (a) Cubist shall have the right, upon [ ]* prior written
notice to Abbott, to conduct during normal business hours a quality assurance
audit and inspection of Abbott's records and production facilities relating to
the manufacture of Product, and follow-up audits as necessary. Such audits and
inspections may be conducted from time to time on a reasonable basis prior to
production of the first commercial Product order placed by Cubist and thereafter
once each calendar year. The duration of such audits shall not exceed two (2)
days and such audits shall be performed by no more than three (3) auditors,
unless Cubist reasonably believes that a longer audit or additional personnel
are necessary and provides its reasons for such belief to Abbott in writing. If
Cubist wishes to perform audits more often than once per year or over a period
in excess of [ ]*, Cubist shall pay Abbott [ ]* Dollars (US$[ ]*) per additional
audit day. If more than three (3) auditors perform the audit, Cubist shall pay
Abbott [ ]* Dollars (US$ [ ]*) per additional auditor. In addition, Cubist shall
have the right at any time during the Term, upon [ ]* prior written notice to
Abbott, to conduct any audits specifically mandated by any regulatory authority
or to respond to specific questions from any regulatory authority. Visits by
Cubist to Abbott's production facilities may involve the transfer of
Confidential Information and shall be subject to the terms of Article 12 hereof.
The results of such audits and inspections shall be considered Confidential
Information under Article 12 and shall not be disclosed to third persons,
including but not limited to the FDA and other government regulatory agencies,
unless required by law and upon prior written notice to Abbott. In the event,
Abbott fails to meet cGMPs or the Product Specifications, Abbott will be
responsible, at Abbott's expense, for (i) conducting an investigation to define
the probable causes for the failure, (ii) providing an acceptable cGMPs
investigation report to Cubist for review and written approval and (iii)
achieving compliance with cGMPs.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -14-

     (b) In the event the FDA or other governmental regulatory agency notifies
Abbott that it intends to visit or inspect the Abbott production facilities
relating to the manufacture of Product. Abbott shall promptly provide notice of
such visit or inspection to Cubist and Cubist shall have the right to
participate in such visit or inspection. Abbott shall advise Cubist immediately
if an authorized agent of the FDA or other governmental regulatory agency visits
the Abbott production facilities relating to the manufacture of Product without
prior notice. Abbott shall furnish to Cubist the report by such agency of such
visit to the Abbott production facilities relating to the manufacture of Product
within [ ]* of Abbott's receipt of such report.

     8.4.9 INSPECTION OF PRODUCT. Cubist shall have a period of [ ]* from the
date of receipt of a shipment of Product to inspect and reject such shipment on
the grounds that it does not conform with the Product Specifications. If Cubist
rejects such shipment, it shall promptly so notify Abbott and provide to Abbott
samples of such shipment for testing. If Abbott tests such shipment and
determines that it did conform to the Product Specifications, the parties shall
submit samples of such shipment to a mutually acceptable independent laboratory
for testing. If such independent laboratory determines that the shipment
conformed to the Product Specifications, Cubist shall bear all expenses of
shipping and testing such shipment samples. If Abbott or such independent
laboratory confirms that such shipment did not meet the Product Specifications,
Abbott shall replace, at no cost to Cubist, that portion of the Product shipment
which does not conform to the Product Specifications, and shall bear all
expenses of shipping and testing the shipment samples. Any nonconforming portion
of any shipment shall be disposed of as directed by Abbott, at Abbott's expense.
Any Product that Cubist does not reject pursuant to this Subparagraph 8.4.9
shall be deemed accepted and all claims with respect to Product not conforming
with Product Specifications shall be deemed waived by Cubist, except as to
latent defects which are not reasonably discoverable. Notwithstanding the
foregoing to the contrary, this Subparagraph 8.4.9 shall not limit any liability
of Abbott under Subparagraph 8.8.4 or release Abbott from its warranty under
Subparagraph 8.8.3(b). Cubist shall not be required to pay Abbott for any
Product which has been properly rejected pursuant to this Paragraph 8.4.9.
Abbott shall replace rejected Product at no additional cost to Cubist as soon as
reasonably possible after receipt of test results confirming nonconformance with
the Product Specifications.

     8.4.10 NOTIFICATION OF COMPLAINTS. Cubist shall notify Abbott of any
Product complaints involving Abbott's manufacture or packaging in sufficient
time to allow Abbott to evaluate the complaints and assist Cubist in responding
to such complaints.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -15-

     8.4.11 PRODUCT RECALLS. If (a) any regulatory authority withdraws the
approval to sell the Product in such country or issues a directive or request
that the Product be recalled for product safety reasons relating to the Product
or (b) any regulatory authority or court of competent jurisdiction issues a
request, directive or order that the Product be recalled, or (c) Cubist or
Abbott shall reasonably determine that the Product should be recalled, both
parties shall collaboratively take all appropriate corrective actions, and shall
cooperate in any governmental investigations surrounding the recall. In the
event that such recall results from any cause or event arising from defective
manufacture, storage or handling of the Product by Abbott (excluding defects
relating to Bulk Drug, packaging or labeling supplied by or prepared at the
direction of Cubist), Abbott shall be responsible for all expenses of the recall
and Abbott shall promptly replace such Product at no additional cost to Cubist
consistent with directions received from the appropriate governmental authority.
In all other cases, Cubist shall be responsible for the expenses of recall,
including the cost of replacement Product. For the purposes of this Agreement,
the expenses of recall shall include, without limitation, the expenses of
notification and destruction or return of the recalled Product and all other
costs incurred in connection with such recall, but shall not include lost
profits of either party.

     8.5. PRICE AND PAYMENT.

     8.5.1 PRICE. Product shall be delivered by Abbott at prices set forth on
Exhibit 8.5.1 of this Agreement.

     8.5.2 PAYMENT. Abbott shall invoice Cubist upon delivery of Product. Cubist
shall make payment net [ ]* from the date of receipt of Abbott's invoice.

     8.5.3 TAXES. Any federal, state, county or municipal sales or use tax,
excise, customs charges, duties or similar charge, or any other tax assessment
(other than that assessed against income), license, fee or other charge lawfully
assessed or charged on the manufacture, sale or transportation of Product sold
pursuant to this Agreement shall be paid by Cubist.

     8.6 DELIVERY.

     Abbott shall deliver Product to Cubist, F.O.B. Abbott's plant at McPherson,
Kansas or at any other Abbott plant the parties may agree to in writing. Title
shall pass to Cubist at such point. Shipment shall be via a carrier designated
by Cubist.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -16-

     8.7 ORDERS AND FORECASTS.

     8.7.1 FIRST YEAR ESTIMATE. Cubist shall, within [ ]* after filing its NDA,
ANDA or equivalent foreign regulatory submission for the Product, provide Abbott
with a written estimate of Cubist's monthly requirements for the Product from
Abbott for the first Contract Year Abbott acknowledges that such quantities are
estimates only.

     8.7.2 TRUST ORDER. Abbott and Cubist shall cooperate fully in estimating
and scheduling production for the first commercial order of Product to be placed
by Cubist with Abbott in anticipation of regulatory approval of Product.

     8.7.3 FIRST FIRM QUARTERLY ORDER AND ANNUAL FORECAST. Cubist shall place
its first firm quarterly order approximately [ ]* in advance of the anticipated
NDA approval date, ANDA approval date or equivalent foreign regulatory
submission approval date, or desired Product availability date for the Product
to be available for the first quarter of commercial launch. [ ]*.

     8.7.4 ROLLING FORECAST. Thereafter, Cubist shall provide within the
first [  ]* of each quarter to Abbott a rolling [ ]* projection of
requirements with the first [ ]* of such projection consisting of firm
purchase orders and the remaining [ ]* of such projection consisting of
Cubist's best estimate forecast of its Product requirements.

     8.7.5 PURCHASE ORDER ACCEPTANCE. Within [ ]* after receipt of Cubist's firm
purchase orders for Product, Abbott shall confirm to Cubist its acceptance of
the purchase order, delivery date and quantity of Product ordered by Cubist.

     8.7.6 FIRM QUARTERLY ORDER CHANGES. If, due to significant unforeseen
circumstances, Cubist requests changes to firm quarterly orders with less
than [  ]* notice, Abbott shall attempt within reasonable manufacturing
capabilities and efficiencies to accommodate the changes. Abbott shall advise
Cubist of the costs associated with making any such change and Cubist shall
be deemed to have accepted the obligation to pay Abbott for such costs if
Cubist indicates to Abbott that Abbott should proceed to make the change;
provided that if the change requested is a reschedule of a firm order for
delivery within the same calendar quarter no additional fee shall be assessed.

     8.7.7 PURCHASE ORDER TERMS. Each purchase order or any acknowledgment
thereof, whether printed, stamped, typed, or written, shall be governed by the
terms of this Agreement and none of the provisions of

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -17-

such purchase order or acknowledgment shall be applicable except those
specifying quantity ordered, delivery dates, special shipping instructions and
invoice information.

     8.8 GUARANTEES AND WARRANTIES.

     8.8.1 CUBIST'S GUARANTEE. Cubist guarantees to Abbott that all Bulk Drug
delivered to Abbott pursuant to this Agreement shall, at the time of delivery,
not be adulterated or misbranded within the meaning of the Federal Food, Drug
and Cosmetic Act, as amended, (the "Act") or within the meaning of any
applicable state or municipal law in which the definitions of adulteration and
misbranding are substantially the same as those contained in the Act, as the Act
and such laws are constituted and effective at the time of delivery and will not
be an article which may not under the provisions of Sections 404 and 505 of the
Act be introduced into interstate commerce. Cubist further warrants to Abbott
that Bulk Drug supplied to Abbott hereunder shall meet the Bulk Drug
Specifications set forth on Exhibit 1.2. Cubist further guarantees that all
Product Specifications Cubist provides to Abbott shall conform with the
appropriate Cubist filing with either the FDA or its foreign equivalent.

     8.8.2 ABBOTT'S GUARANTEE. Abbott guarantees to Cubist that Product Abbott
delivers to Cubist pursuant to this Agreement shall, at the time of delivery,
not be adulterated or misbranded within the meaning of the Act, or within the
meaning of any applicable state or municipal law in which the definitions of
adulteration and misbranding are substantially the same as those contained in
the Act, as the Act and such laws are constituted and effective at the time of
delivery and will not be an article which may not under the provisions of
Sections 404 and 505 of such Act be introduced into interstate commerce.

     8.8.3 ABBOTT'S PRODUCT WARRANTY. Abbott represents and warrants to Cubist
that Product Abbott delivers to Cubist pursuant to this Agreement shall be free
from defects in material and workmanship and shall be manufactured (a) in
accordance and conformity with the Product Specifications and (b) in compliance
with all applicable statutes, laws, rules or regulations, including those
relating to the environment, food or drugs and occupational health and safety,
including, without limitation, those enforced or promulgated by the FDA
(including, without limitation, compliance with cGMPs). Abbott further
represents and warrants to Cubist that the performance of its obligations under
this Agreement will not result in a violation or breach of and will not conflict
with or constitute a default under its Certificate of Incorporation or corporate
bylaws or any agreement, contract, commitment or obligation to which Abbott or
any of its Affiliates is a party or by which it is bound.

<PAGE>
                                      -18-

     The foregoing warranties shall not extend to any nonconformity or defect
which relates to or is caused by Bulk Drug that Cubist supplies to Abbott.
Subject to Subparagraph 8.8.4, the replacement provisions of Subparagraph 8.4.2
shall be Cubist's sole and exclusive remedy for non-conforming or defective
Product. ABBOTT MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO
PRODUCT. ALL OTHER WARRANTTES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION,
THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE
ARE HEREBY DISCLAIMED BY ABBOTT. Except as otherwise provided under Subparagraph
8.8.4 with respect to third party claims, neither party shall be liable to the
other for indirect, incidental or consequential damages resulting from any
breach of this Agreement.

     8.8.4 ABBOTT INDEMNIFICATION. Subject to the provisions of Subparagraph
8.8.6, Abbott shall indemnify and hold Cubist, its affiliates, officers,
directors and employees harmless from and against all claims, causes of action,
settlement costs, losses or liabilities of any kind (including reasonable
attorney's fees) related to this Agreement and asserted by third persons which
arise out of or are attributable to (a) any intentional wrongful act or any
negligent act or omission on the part of Abbott's employees, agents or
representatives, (b) Abbott's breach of any representation or warranty set forth
in Subparagraph 8.8.3, or (c) a third party's proprietary rights relating to
Abbott's manufacturing processes used in the manufacture of Product pursuant to
this Agreement. The foregoing indemnification action shall not apply in the
event and to the extent that a court of competent jurisdiction determines that
such losses arose as a result of Cubist's (or any Cubist indemnitee's)
negligence, intentional misconduct or breach of this Agreement.

     8.8.5 CUBIST INDEMNIFICATION. Subject to the provisions of Subparagraphs
8.8.6, Cubist shall indemnify and hold Abbott, its affiliates, officers,
directors and employees harmless from and against all claims, causes of action,
settlement costs, losses or liabilities of any kind (including reasonable
attorney's fees) related to this Agreement and asserted by third persons which
arise out of or are attributable to (a) any intentional wrongful act or any
negligent act or omission on the part of Cubist's employees, agents or
representatives, (b) the use of or lack of safety or efficacy of Drug or Product
except to the extent such claim is based upon a breach of Abbott's
representations or warranties set forth in Subparagraph 8.8.3, and (c) a third
party's proprietary rights relating to the Drug or Product. The foregoing
indemnification action shall not apply in the event and to the extent that a

<PAGE>
                                      -19-

court of competent jurisdiction determines that such losses arose as a result of
Abbott's (or any Abbott indemnitee's) negligence, intentional misconduct or
breach of this Agreement.

     8.8.6 CONDITIONS OF INDEMNIFICATION. If either party seeks indemnification
from the other hereunder, it shall promptly give notice to the other party of
any such claim or suit threatened, made or filed against it which forms the
basis for such claim of indemnifcation and shall cooperate fully with the other
party in the investigation and defense of all such claims or suits. The
indemnifying party shall have the option to assume the other party's defense in
any such claim or suit with counsel reasonably satisfactory to the other party.
No settlement or compromise shall be binding on a party hereto without its prior
written consent, such consent not to be unreasonably withheld.

                            ARTICLE 9. PRESS RELEASE
                            ------------------------

         Neither party shall make any public announcement concerning the
transactions contemplated herein, or make any public statement which includes
the name of the other party or any of its affiliates or subsidiaries, or
otherwise use the name of the other party or any of its affiliates or
subsidiaries in any public statement or document, except as may be required by
law or judicial order, without the written consent of the other party, which
consent shall not be unreasonably withheld. Subject to any legal or judicial
disclosure obligation, any such public announcement proposed by a party that
names the other party shall first be provided in draft to the other party. The
other party shall have [ ]* to review and approve such draft prior to the issue
or publication of the announcement.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -20-

                    ARTICLE 10. INTELLECTUAL PROPERTY RIGHTS
                    ----------------------------------------

     10.1. [ ]*

     10.2. [ ]*

                        ARTICLE 11. TERM AND TERMINATION
                        --------------------------------

     11.1 TERM. This Agreement shall commence on the Effective Date and the
initial Term shall expire at the end of the [   ]* Contract Year. Thereafter,
the Agreement shall continue automatically until terminated. This Agreement
may be terminated upon expiration of the Term or at anytime thereafter [   ]*
written notice from one party to the other.

     11.2 TERMINATION OF PRODUCT DEVELOPMENT PROJECT. The Project as described
in Article 2 may be terminated by either party at any time by [ ]* prior written
notice if such party makes a good faith determination that the Product is not
technically or commercially feasible. If the Project is terminated, Abbott shall
advise Cubist of Abbott's actual development costs

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -21-

on the Project incurred prior to such termination. Based upon Abbott's actual
costs and Cubist's payments to Abbott, an appropriate adjustment negotiated in
good faith shall be made. Abbott, if requested by Cubist, shall provide to
Cubist a summary of costs payable pursuant to this Paragraph 11.2. Upon payment
of any adjustment required by this Paragraph 11.2, this Agreement shall
terminate.

     11.3 GENERAL TERMINATION RIGHTS. Either party may terminate this Agreement
by giving to the other [ ]* prior written notice as follows:

     a. Upon the bankruptcy or the insolvency of the other party unless, in the
        case of an involuntary proceeding, it is dismissed within the notice
        period; or

     b. Upon the breach of any warranty or any other material provision of this
        Agreement by the other party if the breach is not cured within [ ]*
        after written notice thereof to the party in default.

     11.4 REIMBURSEMENT UPON TERMINATION. Upon termination pursuant to this
Article 11, Cubist shall reimburse Abbott for Abbott's cost of all supplies
purchased and on hand or on order, if such supplies were ordered by Abbott based
on firm purchase orders or Cubist estimates of its requirements of Product and
such supplies cannot be reasonably used by Abbott for other purposes and cannot
be cancelled. Abbott shall use reasonable efforts to mitigate the costs of
non-cancelable orders. Abbott shall invoice Cubist for amounts due hereunder.
Payment shall be made pursuant to Subparagraph 8.5.2.

     11.5 RETURN OF INVENTORY. In the event of any termination, within [ ]* of
said termination, Abbott shall return any remaining inventory of Bulk Drug and
Product to Cubist at Cubist's expense, unless such termination shall have been
as a result of a breach of this Agreement by Abbott, in which case such
inventory shall be returned at Abbott's expense.

     11.6 RETURN OF EQUIPMENT. In the event of any termination, within [ ]* of
said termination, Abbott shall return to Cubist at Cubist's expense any
equipment purchased with Cubist funds, provided that Abbott has not purchased
such equipment from Cubist pursuant to Subparagraph 8.4.4.

     11.7 SURVIVAL. Termination of this Agreement shall not affect rights and
obligations of either party that may have accrued prior to the effective date of
termination or any obligation specifically stated to survive termination. The
provisions of Articles 1-2 and Paragraphs 8.8, 10, 11, 12, and 13 shall survive
any expiration or termination of this Agreement.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -22-

                      ARTICLE 12. CONFIDENTIAL INFORMATION
                      ------------------------------------

     12.1 It is recognized by the parties that, during the Term of this
Agreement, the parties will exchange Confidential Information. Abbott agrees
that it shall not disclose or use for Abbott's benefit (other than as provided
herein) or for the benefit of any third person Confidential Information received
from Cubist. Cubist agrees that it shall not disclose or use for Cubist's
benefit (other than as provided herein) or for the benefit of any third person
Confidential Information received from Abbott.

     12.2 Notwithstanding the above, nothing contained in this Agreement shall
preclude Cubist or Abbott from utilizing Confidential Information as may be
necessary in prosecuting patent rights of the parties pursuant to Article 10, or
obtaining governmental marketing approvals, or in manufacturing Product pursuant
to the terms and conditions of this Agreement. The obligations of the parties
relating to Confidential Information shall expire [ ]* after the termination of
this Agreement.

                            ARTICLE 13. MISCELLANEOUS
                            -------------------------

     13.1 FORCE MAJEURE.

     13.1.1 EXCUSABLE DELAY. Any delay in the performance of any of the duties
or obligations of either party hereto (except the payment of money) shall not be
considered a breach of this Agreement and the time required for performance
shall be extended for a period equal to the period of such delay, provided that
such delay has been caused by or is the result of any acts of God, acts of the
public enemy, insurrections, riots, embargoes, labor disputes, including
strikes, lockouts, job actions, boycotts, fires, explosions, floods, shortages
of material or energy, or other unforeseeable causes beyond the control and
without the fault or negligence of the party so affected. The affected party
shall give prompt notice to the other party of such cause, and shall take
promptly whatever reasonable steps are necessary to relieve the effect of such
cause.

     13.1.2 TRANSFER OF PRODUCTION. If Abbott becomes subject to an event of
force majeure or problems are encountered which interfere with production of
Product at Abbott's McPherson, Kansas plant, the parties shall agree mutually on
implementation of an agreed upon action plan to transfer production to another
Abbott plant. The parties shall meet, after the execution of this Agreement and
at the request of either party, to discuss and define such an action plan.

<PAGE>
                                      -23-

     13.2 NOTICES. All notices hereunder shall be delivered either: (a)
personally; (b) by facsimile and confirmed by first class mail (postage
prepaid); (c) by registered or certified mail (postage prepaid); or (d) by
overnight courier service to the following addresses of the respective parties:

          To:      Cubist Pharmaceuticals, Inc.
                   24 Emily Street
                   Cambridge, MA  02139 U.S.A.
                   Attention: Dr. Alan Watson
                   Facsimile: (617) 576-0271

          To:      Hospital Products Division
                   Abbott Laboratories
                   200 Abbott Park Road
                   Abbott Park, Illinois  60064-3537 U.S.A.
                   Attention: President
                   Facsimile: 847-937-2927

                   With copy to:     Divisional Vice President
                                     Domestic Legal Operations
                                     100 Abbott Park Road
                                     D-322, AP6D
                                     Abbott Park, Illinois  60064-3500 U.S.A.
                                     Facsimile: 847-938-1206

     Notices shall be effective upon receipt if personally delivered or
delivered by facsimile and confirmed by first class mail, on the third business
day following the date of registered or certified mailing or on the first
business day following the date of delivery to the overnight courier. A party
may change its address listed above by written notice to the other party.

     13.3 CHOICE OF LAW. This Agreement shall be construed, interpreted and
governed by the laws of the State of Illinois, except for its choice of law
rules.

     13.4 ALTERNATIVE DISPUTE RESOLUTION. The parties recognize that bona fide
disputes may arise which relate to the parties' rights and obligations under
this Agreement. The parties agree that any such dispute shall be resolved by ADR
in accordance with the procedure set forth in Exhibit 13.4.

<PAGE>
                                      -24-

     13.5 ASSIGNMENT. Neither party shall assign this Agreement nor any part
thereof without the prior written consent of the other party; which shall not be
unreasonably withheld, PROVIDED, HOWEVER, (a) either party may assign this
Agreement to one of its wholly-owned subsidiaries without such consent; or (b)
either party, without such consent, may assign or sell the same in connection
with the transfer or sale of substantially all of its business to which this
Agreement pertains or in the event of its merger or consolidation with another
company. Any permitted assignee shall assume all obligations of its assignor
under this Agreement. No assignment shall relieve any party of responsibility
for the performance of any accrued obligation which such party then has
hereunder.

     13.6 ENTIRE AGREEMENT. This Agreement, together with the Exhibits
referenced and incorporated herein, constitute the entire agreement between the
parties concerning the subject matter hereof and supersede all written or oral
prior agreements or understandings with respect thereto.

     13.7 SEVERABILITY. This Agreement is subject to the restrictions,
limitations, terms and conditions of all applicable governmental regulations,
approvals and clearances. If any term or provision of this Agreement shall for
any reason be held invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof, and this Agreement shall be interpreted and construed as if
such term or provision, to the extent the same shall have been held to be
invalid, illegal or unenforceable, had never been contained herein.

     13.8 WAIVER - MODIFICATION OF AGREEMENT. No waiver or modification of any
of the terms of this Agreement shall be valid unless in writing and signed by
authorized representatives of both parties. Failure by either party to enforce
any such rights under this Agreement shall not be construed as a waiver of such
rights, nor shall a waiver by either party in one or more instances be construed
as constituting a continuing waiver or as a waiver in other instances.

     13.9 INSURANCE CLAUSE. Cubist shall, at its sole cost and expense, obtain
and keep in force general liability insurance with bodily injury, death and
property damage limits of [ ]* Dollars (US$[ ]*) per occurrence and [ ]* Dollars
(US$[ ]*) in the aggregate including product liability coverage. Upon the
Effective Date, Cubist shall furnish to Abbott a certificate of insurance signed
by an authorized representative of Cubist's insurance underwriter evidencing the
insurance coverage required by this Agreement and providing for at least [ ]*
prior written notice to Abbott of any cancellation, termination, material change
or reduction of such insurance coverage.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -25-

     13.10 DISTRIBUTION AGREEMENT. If requested by Cubist, Abbott agrees to
negotiate in good faith with Cubist for a separate contract for distributing
finished product.

     13.11 [   ]*

     13.12 EXHIBITS. All Exhibits referred to herein are hereby incorporated by
reference.

     13.13 MISCELLANEOUS.

     13.13.1 PROCESS REWORK. Process rework created as a result of Cubist's
changes shall be billed separately at a reasonable fee mutually agreed upon in
writing.

     13.13.2 POSTPONEMENT OF SCHEDULED PRODUCTION RUN. If Cubist postpones a
scheduled production run less than sixty (60) days prior to the production date,
then Cubist shall pay to Abbott [ ]* Dollars (US$[ ]*) for this change;
notwithstanding the foregoing, if Abbott is able to fill such scheduled time
period with another production run for a third party, Cubist will receive a
refund of such fee.

     13.13.3 SUB-LOTS. Should Cubist desire Abbott to split a manufacturing lot
of material into several sub-lots during packaging, there is a split fee of [ ]*
Dollars (US$[ ]*) for each sub-lot packaged off due Abbott.

     13.13.4 COLD STORAGE FEE. A cold storage fee shall he due and payable to
Abbott if Cubist stores Product at Abbott's plant after such Product's final
release. The fee shall be [ ]* (US$[ ]*) per pallet per month or any part
thereof.

     13.13.5 SHIPMENT PER BATCH. Abbott shall make up to two (2) shipments to
Cubist of Product per batch at no charge to Cubist. Any other shipments
requested shall be at a fee of [ ]* Dollars (US$[ ]*) per shipment plus shipping
costs.

     13.13.6 DEBARMENT WARRANT. Abbott and Cubist represent and warrant that
neither party uses nor will in the future use in any capacity the services of
any person debarred under Section (a) or (b) of 21 U.S.C. Section 335a.

*  Confidential treatment requested: Material has been omitted and filed with
   the Commission.

<PAGE>
                                      -26-

     The parties intending to be bound by the terms and conditions hereof have
caused this Agreement to be signed by their duly authorized representatives on
the date first above written.

ABBOT LABORATORIES                          CUBIST PHARMACEUTICALS, INC.

         /S/ RICHARD A. GONZALEZ                     /S/ SCOTT M. ROCKLAGE
--------------------------------            -----------------------------------
By (Signature)                              By (Signature)

         RICHARD A. GONZALEZ                         SCOTT M. ROCKLAGE
--------------------------------            -----------------------------------
Name (Printed)                              Name (Printed)

         PRESIDENT                                   PRESIDENT AND CEO
--------------------------------            -----------------------------------
Title                                       Title<PAGE>

EXHIBIT 10.34

                                                                       EXHIBIT C

                          TRANSKARYOTIC THERAPIES, INC.

                          REGISTRATION RIGHTS AGREEMENT

                  REGISTRATION RIGHTS AGREEMENT, dated as of June 9, 2000, among
the investors listed on Schedule I hereto (the "Investors") and Transkaryotic
Therapies, Inc., a Delaware corporation (the "Company").

                                 R E C I T A L S

                  WHEREAS, the Investors have, pursuant to the terms of the
Stock Purchase Agreement, dated as of May 18, 2000, by and among the Company and
the Investors (the "Purchase Agreement"), agreed to purchase shares of Series A
Convertible Preferred Stock, par value $0.01 per share, of the Company (the
"Series A Preferred Stock"); and

                  WHEREAS, the shares of Series A Preferred Stock are
convertible into shares of common stock, par value $0.01 per share, of the
Company (the "Common Stock"); and

                  WHEREAS, the Company has agreed, as a condition precedent to
the Investors' obligations under the Purchase Agreement, to grant the Investors
certain registration rights; and

                  WHEREAS, the Company and the Investors desire to define the
registration rights of the Investors on the terms and subject to the conditions
herein set forth.

                  NOW, THEREFORE, in consideration of the foregoing premises and
for other good and valuable consideration, the parties hereby agree as follows:

                  SECTION  1. DEFINITIONS

                  As used in this Agreement, the following terms have the
respective meaning set forth below:

                  (a) COMMISSION: shall mean the Securities and Exchange
Commission or any other federal agency at the time administering the Securities
Act;

                  (b) EXCHANGE ACT: shall mean the Securities Exchange Act of
1934, as amended and the rules and regulations of the Commission issued under
such Act as they may, from time to time, be in effect;

<PAGE>

                  (c) HOLDER: shall mean the Investors and any persons or
entities to whom the rights granted under this Agreement are transferred by any
Investor in accordance with the terms of this Agreement;

                  (d) INITIATING HOLDER: shall mean any Holder or Holders who in
the aggregate are Holders of more than 50% of the then outstanding Registrable
Securities;

                  (e) PERSON: shall mean an individual, partnership, joint-stock
company, corporation, trust or unincorporated organization, and a government or
agency or political subdivision thereof;

                  (f) REGISTER, REGISTERED and REGISTRATION: shall mean a
registration effected by preparing and filing a registration statement in
compliance with the Securities Act (and any post-effective amendments filed or
required to be filed) and the declaration or ordering of effectiveness of such
registration statement;

                  (g) REGISTRABLE SECURITIES: shall mean (A) shares of Common
Stock issuable upon conversion of the shares of Series A Preferred Stock and (B)
any additional shares of Common Stock acquired by the Investors, and (C) any
stock of the Company issued as a dividend or other distribution with respect to,
or in exchange for or in replacement of, the shares of Series A Preferred Stock
or Common Stock referred to in clause (A) or (B); PROVIDED, HOWEVER, that shares
of Common Stock which are Registrable Shares shall cease to be Registrable
Shares upon (i) any sale pursuant to a Registration Statement or Rule 144 under
the Securities Act or (ii) any sale in any manner to a person or entity which is
not entitled to the rights provided by this Agreement. Wherever reference is
made in this Agreement to a request or consent of holders of a certain
percentage of Registrable Shares, the determination of such percentage shall
include shares of Common Stock issuable upon conversion of the Shares even if
such conversion has not been effected.

                  (h) REGISTRATION EXPENSES: shall mean all expenses incurred by
the Company in compliance with Sections 2(a), (b) and (c) hereof, including,
without limitation, all registration and filing fees, printing expenses, fees
and disbursements of counsel for the Company, fees and expenses of one counsel
for all the Holders in an amount not to exceed $15,000, blue sky fees and
expenses and the expense of any special audits incident to or required by any
such registration (but excluding the compensation of regular employees of the
Company, which shall be paid in any event by the Company), but excluding Selling
Expenses;

                  (i) SECURITY, SECURITIES: shall have the meaning set forth in
Section 2(1) of the Securities Act;

                  (j) SECURITIES ACT: shall mean the Securities Act of 1933, as
amended; and

                  (k) SELLING EXPENSES: shall mean all underwriting discounts
and selling commissions applicable to the sale of Registrable Securities and all
fees and disbursements of counsel for each of the Holders other than fees and
expenses of one counsel for all the Holders in an amount not to exceed $15,000.

                                       -2-
<PAGE>

                  SECTION 2. REGISTRATION RIGHTS

                  (a) REQUESTED REGISTRATION.

                  (i) REQUEST FOR REGISTRATION. If the Company shall receive
from an Initiating Holder, at any time, a written request that the Company
effect any registration with respect to all or a part of the Registrable
Securities, the Company will:

                  (1) promptly give written notice of the proposed registration,
qualification or compliance to all other Holders; and

                  (2) as soon as practicable, use its commercially reasonable
efforts to effect such registration (including, without limitation, filing
post-effective amendments and effecting appropriate qualification under
applicable blue sky or other state securities laws and appropriate compliance
with applicable regulations issued under the Securities Act) as may be so
requested and as would permit or facilitate the sale and distribution of all or
such portion of such Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any Holder or
Holders joining in such request as are specified in a written request received
by the Company within 10 business days after written notice from the Company is
given under Section 2(a)(i)(1) above; PROVIDED that the Company may effect such
registration on such available form of registration statement as the Company
determines (but, in the case of an underwritten offering, shall include such
additional information, such as a customary "Business" section, as the
Initiating Holders shall reasonably request); and PROVIDED further that the
Company shall not be obligated to effect, or take any action to effect, any such
registration pursuant to this Section 2(a):

                                     (w) Within 180 days of the effective date
                  of the most recent registration pursuant to this Section 2 in
                  which securities held by the requesting Holder could have been
                  included for sale or distribution.

                                     (x) In any particular jurisdiction in which
                  the Company would be required to qualify to do business as a
                  foreign corporation or execute a general consent to service of
                  process in effecting such registration, qualification or
                  compliance, unless the Company is already subject to
                  qualification to do business or service in such jurisdiction
                  and except as may be required by the Securities Act or
                  applicable rules or regulations thereunder;

                                     (y) After the Company has effected (A) two
                  (2) registrations pursuant to this Section 2(a) or (B) three
                  (3) registrations pursuant to Section 2(a) or 2(c), whichever
                  occurs sooner, and such registrations have been declared or
                  ordered effective; or

                                     (z) If the Registrable Securities requested
                  by all Holders to be registered pursuant to such request do
                  not have an anticipated

                                       -3-
<PAGE>

                  aggregate public offering price (before any
                  underwriting discounts and commissions) of not less than
                  $15,000,000.

                  The registration statement filed pursuant to the request of
the Initiating Holders may, subject to the provisions of Section 2(a)(ii) below,
include other securities of the Company which are held by Persons who, by virtue
of agreements with the Company, are entitled to include their securities in any
such registration ("Other Stockholders"). In the event any Holder requests a
registration pursuant to this Section 2(a) in connection with a distribution of
Registrable Securities to its partners, the registration shall provide for the
resale by such partners, if requested by such Holder if distributee partners are
transferees under the last paragraph of this Section 2(a)(i)(2).

                  The registration rights set forth in this Section 2 may be
assigned by an Investor to (i) any person or entity to which at least 15% of the
Registrable Securities held by such Investor are transferred by such Investor,
provided that the transferee provides written notice of such assignment to the
Company and agrees in writing to be bound hereby or (ii) to any partner of such
Investor (or nominee or subsidiary of such partner), and such transferee shall
be deemed an "Investor" for purposes of this Agreement;.

                  (ii) UNDERWRITING. If the Initiating Holders intend to
         distribute the Registrable Securities covered by their request by
         means of an underwriting, they shall so advise the Company as
         a part of their request made pursuant to Section 2(a). If Other
         Stockholders request such inclusion, the Holders shall offer to include
         the securities of such Other Stockholders in the underwriting and may
         condition such offer on their acceptance of the further applicable
         provisions of this Section 2. The Holders whose shares are to be
         included in such registration and the Company shall (together with all
         Other Stockholders proposing to distribute their securities through
         such underwriting) enter into an underwriting agreement in customary
         form with the representative of the underwriter or underwriters
         selected for such underwriting by the Initiating Holders and reasonably
         acceptable to the Company. Notwithstanding any other provision of this
         Section 2(a), if the representative advises the Holders in writing that
         marketing factors require a limitation on the number of shares to be
         underwritten, the securities of the Company held by Other Stockholders
         shall be excluded from such registration to the extent so required by
         such limitation. If, after the exclusion of such shares, further
         reductions are still required, the number of shares included in the
         registration by each Holder shall be reduced on a pro rata basis (based
         on the number of shares held by such Holder), by such minimum number of
         shares as is necessary to comply with such request. No Registrable
         Securities or any other securities excluded from the underwriting by
         reason of the underwriter's marketing limitation shall be included in
         such registration. If any Other Stockholder who has requested inclusion
         in such registration as provided above disapproves of the terms of the
         underwriting, such person may elect to withdraw therefrom by written
         notice to the Company, the underwriter and the Initiating Holders. The
         securities so withdrawn shall also be withdrawn from registration. If
         the underwriter has not limited the number of Registrable Securities or
         other securities to be underwritten, the Company and officers and
         directors of the Company may include its or their securities for its or
         their own account in such registration if the representative so

                                       -4-
<PAGE>

         agrees and if the number of Registrable Securities and other
         securities which would otherwise have been included in such
         registration and underwriting will not thereby be limited.

                  (b) COMPANY REGISTRATION.

                  (i) If the Company shall determine to register any of its
         equity securities either for its own account or for the account of
         Other Stockholders, other than a registration relating solely to
         employee benefit plans, or a registration relating solely to a
         Commission Rule 145 transaction, or a registration on any registration
         form which does not permit secondary sales or does not include
         substantially the same information as would be required to be included
         in a registration statement covering the sale of Registrable
         Securities, the Company will:

                  (1) promptly give to each of the Holders a written notice
            thereof (which shall include a list of the jurisdictions in which
            the Company intends to attempt to qualify such securities under the
            applicable blue sky or other state securities laws); and

                  (2) include in such registration (and any related
            qualification under blue sky laws or other compliance), and in any
            underwriting involved therein, all the Registrable Securities
            specified in a written request or requests, made by the Holders
            within fifteen (15) days after receipt of the written notice from
            the Company described in clause (1) above, except as set forth in
            Section 2(b)(ii) below. Such written request may specify all or a
            part of the Holders' Registrable Securities. In the event any Holder
            requests inclusion in a registration pursuant to this Section 2(b)
            in connection with a distribution of Registrable Securities to its
            partners, the registration shall provide for the resale by such
            partners, if requested by such Holder if distributee partners are
            transferees under the last paragraph of Section 2(a)(i)(2);

         PROVIDED that the Company shall have the right to postpone or withdraw
         any registration effected pursuant to this Section 2(b) without
         obligation to any Holder.

                  (ii) UNDERWRITING.

                  (1) If the registration of which the Company gives notice is
            for a registered public offering involving an underwriting initiated
            by the Company or initiated pursuant to a demand by Other
            Stockholders, the Company shall so advise each of the Holders as a
            part of the written notice given pursuant to Section 2(b)(i)(1). In
            such event, the right of each of the Holders to registration
            pursuant to this Section 2(b) shall be conditioned upon such
            Holders' participation in such underwriting and the inclusion of
            such Holders' Registrable Securities in the underwriting to the
            extent provided herein. The Holders whose shares are to be included
            in such registration shall (together with the Company and the Other
            Stockholders distributing their securities through such
            underwriting) enter into an underwriting agreement in customary form
            with the representative of the underwriter or underwriters selected
            for underwriting by the Company.

                                       -5-
<PAGE>

                  (2) Notwithstanding any other provision of this Section 2(b),
            if the underwriting is initiated by the Company and if the
            representative determines that marketing factors require a
            limitation on the number of shares to be underwritten, the Company
            shall have priority in including shares in the underwriting and the
            representative may (subject to the allocation priority set forth
            below) limit the number of Registrable Securities to be included in
            the registration and underwriting. The Company shall so advise all
            holders of securities requesting registration, and the number of
            shares of securities that are entitled to be included in the
            registration and underwriting shall be allocated in the following
            manner: The securities of the Company held by officers, directors
            and Other Stockholders of the Company (other than Registrable
            Securities and other than securities held by Other Stockholders)
            shall be excluded from such registration and underwriting to the
            extent required by such limitation, and, if a limitation on the
            number of shares is still required, the number of shares that may be
            included in the registration and underwriting by each of the Holders
            and Other Stockholders shall be reduced, on a pro rata basis (based
            on the number of shares held by such Holder or Other Stockholder),
            by such minimum number of shares as is necessary to comply with such
            limitation. If any of the Holders or any officer, director or Other
            Stockholder disapproves of the terms of any such underwriting, he
            may elect to withdraw therefrom by written notice to the Company and
            the underwriter. Any Registrable Securities or other securities
            excluded or withdrawn from such underwriting shall be withdrawn from
            such registration.

                  (3) Notwithstanding any other provision of this Section 2(b),
            if the underwriting is initiated pursuant to a demand by Other
            Stockholders and if the representative determines that marketing
            factors require a limitation on the number of shares to be
            underwritten, the Other Stockholders shall have priority in
            including shares in the underwriting and the representative may
            (subject to the allocation priority set forth below) limit the
            number of Registrable Securities to be included in the registration
            and underwriting. The Company shall so advise all holders of
            securities requesting registration, and the number of shares of
            securities that are entitled to be included in the registration and
            underwriting shall be allocated in the following manner: The
            securities of the Company held by the Company and officers and
            directors of the Company (other than Other Stockholders) shall be
            excluded from such registration and underwriting to the extent
            required by such limitation, and, if a limitation on the number of
            shares is still required, the number of shares that may be included
            in the registration and underwriting by each of the Holders shall be
            reduced, on a pro rata basis (based on the number of shares held by
            such Holder), by such minimum number of shares as is necessary to
            comply with such limitation. If any of the Holders or the Company,
            or any officer or director of the Company disapproves of the terms
            of any such underwriting, he may elect to withdraw therefrom by
            written notice to the Company and the underwriter. Any Registrable
            Securities or other securities excluded or withdrawn from such
            underwriting shall be withdrawn from such registration.

                                       -6-
<PAGE>

                  (c) FORM S-3. The Holders shall have the right to request
three (3) registrations on Form S-3 (such requests shall be in writing and shall
state the number of shares of Registrable Securities to be disposed of and the
intended method of disposition of shares by such holders), subject only to the
following:

                  (i) The Company shall not be required to effect a registration
         pursuant to this Section 2(c) unless the Holder or Holders requesting
         registration propose to dispose of shares of Registrable Securities
         having an aggregate price to the public (before deduction of
         underwriting discounts and expenses of sale) of more than $10,000,000;

                  (ii) The Company shall not be required to effect a
         registration pursuant to this Section 2(c) within 180 days of the
         effective date of the most recent registration pursuant to this Section
         2 in which securities held by the requesting Holder could have been
         included for sale or distribution;

                  (iii) The Company shall not be required to effect a
         registration pursuant to this Section 2(c) after the Company has
         effected (A) two (2) registrations pursuant to Section 2(a) or (B)
         three (3) registrations pursuant to Section 2(a) or this Section 2(c),
         whichever occurs sooner, and such registrations have been declared or
         ordered effective; and

                  (iv) The Company shall not be obligated to effect any
         registration pursuant to this Section 2(c) in any particular
         jurisdiction in which the Company would be required to qualify to do
         business as a foreign corporation or execute a general consent to
         service of process in effecting such registration, qualification or
         compliance, unless the Company is already subject to qualification to
         do business or service in such jurisdiction and except as may be
         required by the Securities Act or applicable rules or regulations
         thereunder.

                  The Company shall give written notice to all Holders of the
receipt of a request for registration pursuant to this Section 2(c) and shall
provide a reasonable opportunity (not to exceed 20 days after the date of such
notice) for other Holders to participate in the registration, provided that if
the registration is for an underwritten offering, the terms of Section 2(a)(ii)
shall apply to all participants in such offering. Subject to the foregoing, the
Company will use its commercially reasonable efforts to effect promptly the
registration of all shares of Registrable Securities on Form S-3 to the extent
requested by the Holder or Holders thereof for purposes of disposition. In the
event any Holder requests a registration pursuant to this Section 2(c) in
connection with a distribution of Registrable Securities to its partners, the
registration shall provide for the resale by such partners, if requested by such
Holder if distributee partners are transferees under the last paragraph of
Section 2(a)(i)(2).

                  (d) EXPENSES OF REGISTRATION. All Registration Expenses
incurred in connection with any registration, qualification or compliance
pursuant to this Section 2 shall be borne by the Company (unless at the request
of the Holders, the registration statement is not filed or is withdrawn, in
which case the Holders shall pay all of the Registration Expenses), and all
Selling Expenses shall be borne by the Holders of the securities so registered
pro rata on the basis of the number of their shares so registered.

                                       -7-
<PAGE>

                  (e) REGISTRATION PROCEDURES. In the case of each registration
effected by the Company pursuant to this Section 2, the Company will keep the
Holders, as applicable, advised in writing as to the initiation of each
registration and as to the completion thereof. At its expense, the Company will:

                  (i) keep such registration effective for a period of ninety
         (90) days or until the Holders (or in the case of a distribution to the
         partners of such Holder, such partners), as applicable, have completed
         the distribution described in the registration statement relating
         thereto, whichever first occurs; PROVIDED, HOWEVER, that in the case of
         any registration of Registrable Securities on Form S-3 which are
         intended to be offered on a continuous or delayed basis, such
         90-day period shall be extended until all such Registrable Securities
         are sold (but in no event later than two years after the effective date
         of the registration statement); provided that Rule 415, or any
         successor rule under the Securities Act, permits an offering on a
         continuous or delayed basis, and PROVIDED FURTHER that applicable rules
         under the Securities Act governing the obligation to
         file a post-effective amendment permit, in lieu of filing a
         post-effective amendment which (y) includes any prospectus required by
         Section 10(a) of the Securities Act or (z) reflects facts or events
         representing a material or fundamental change in the information set
         forth in the registration statement, the incorporation by reference of
         information required to be included in (y) and (z) above to be
         contained in periodic reports filed pursuant to Section 12 or 15(d) of
         the Exchange Act in the registration statement (and the Company is
         eligible to incorporate by reference such information into the
         applicable registration statement);

                  (ii) furnish such number of prospectuses and other documents
         incident thereto as each of the Holders, as applicable, from time to
         time may reasonably request;

                  (iii) notify each Holder of Registrable Securities covered by
         such registration at any time when a prospectus relating thereto is
         required to be delivered under the Securities Act of the happening of
         any event as a result of which the prospectus included in such
         registration statement, as then in effect, includes an untrue statement
         of a material fact or omits to state a material fact required to be
         stated therein or necessary to make the statements therein not
         misleading in the light of the circumstances then existing; and

                  (iv) furnish, on the date that such Registrable Securities are
         delivered to the underwriters for sale, if such securities are being
         sold through underwriters or, if such securities are not being sold
         through underwriters, on the date that the registration statement with
         respect to such securities becomes effective, (1) an opinion, dated as
         of such date, of the counsel representing the Company for the purposes
         of such registration, in form and substance as is customarily given to
         underwriters in an underwritten public offering and reasonably
         satisfactory to a majority in interest of the Holders participating
         in such registration, addressed to the underwriters, if any, and to the
         Holders participating in such registration and (2) a letter, dated as
         of such date, from the independent certified public accountants of the
         Company, in form and substance as is customarily given by independent
         certified public accountants to underwriters in an underwritten public
         offering and reasonably satisfactory to a majority in interest of the
         Holders participating

                                       -8-
<PAGE>

         in such registration, addressed to the underwriters, if any, and if
         permitted by applicable accounting standards, to the Holders
         participating in such registration.

                  (f) LIMITATIONS ON REGISTRATION RIGHTS.

                  (i) Notwithstanding the provisions of this section 2, the
         Company may by written notice to the Holders (x) delay filing a
         Registration Statement requested by a Holder (a "Delayed Registration
         Statement") or (y) require that the Holders immediately cease sales of
         shares under any effective Registration Statement ("Suspended
         Registration Statement"), in any period during which the Company is
         engaged in (i) a registered public offering of the Company, or (ii) any
         activity or transaction or preparations or negotiations for any
         activity or transaction ("Company Activity") that the Company desires
         to keep confidential for business reasons, if the Company determines in
         good faith that the public disclosure requirements imposed on the
         Company under the Securities Act in connection with any such
         Registration Statement would require disclosure of the Company
         Activity; provided, that, (i) in the aggregate, all such delays of
         filing Delayed Registration Statements and/or cessations of sales under
         Suspended Registration Statements shall not exceed 90 days in any
         12-month period and (ii) the Company shall cause any Suspended
         Registration Statement to remain effective for one additional day for
         each day, or any portion of a day, that the Holders were required to
         cease sales of shares thereunder; and

                  (ii) If the Company requires the Holders to cease sales of
         shares pursuant to Section 2f(i) above, the Company shall, as promptly
         as practicable following the termination of the circumstance which
         entitled the Company to do so, give prompt written notice to the
         Holders that such circumstance has terminated and that they may resume
         sales pursuant to the Suspended Registration Statement. If the
         prospectus included in such Suspended Registration Statement has been
         amended to comply with the requirements of the Securities Act, the
         Company shall enclose such revised prospectus with the notice to
         Holders given pursuant to this section 2f(ii) and the Holders shall
         make no offers or sales of shares pursuant to such Suspended
         Registration Statement other than by means of such revised prospectus.

                  (g) INDEMNIFICATION.

                  (i) The Company will indemnify each of the Holders, as
         applicable, each of its officers, directors and partners, and each
         person controlling each of the Holders, with respect to each
         registration which has been effected pursuant to this Section 2, and
         each underwriter, if any, and each person who controls any underwriter,
         against all claims, losses, damages and liabilities (or actions in
         respect thereof) arising out of or based on any untrue statement (or
         alleged untrue statement) of a material fact contained in any
         prospectus, offering circular or other document (including any related
         registration statement, notification or the like) incident to any such
         registration, qualification or compliance, or based on any omission (or
         alleged omission) to state therein a material fact required to be
         stated therein or necessary to make the statements therein not
         misleading, or any violation by the Company of the Securities Act or
         the Exchange Act or any rule or regulation thereunder applicable to the
         Company and relating to action or

                                       -9-
<PAGE>

         inaction required of the Company in connection with any such
         registration, qualification or compliance, and will reimburse each of
         the Holders, each of its officers, directors and partners, and each
         person controlling each of the Holders, each such underwriter and each
         person who controls any such underwriter, for any legal and any other
         expenses reasonably incurred in connection with investigating and
         defending any such claim, loss, damage, liability or action, provided
         that the Company will not be liable in any such case to the extent that
         any such claim, loss, damage, liability or expense arises out of or is
         based on any untrue statement or omission based upon written
         information furnished to the Company by the Holders or underwriter and
         stated to be specifically for use therein.

                  (ii) Each of the Holders will, if Registrable Securities held
         by it are included in the securities as to which such registration,
         qualification or compliance is being effected, indemnify the Company,
         each of its directors and officers and each underwriter, if any, of the
         Company's securities covered by such a registration statement, each
         person who controls the Company or such underwriter, each Other
         Stockholder and each of their officers, directors, and partners, and
         each person controlling such Other Stockholder against all claims,
         losses, damages and liabilities (or actions in respect thereof) arising
         out of or based on any untrue statement (or alleged untrue statement)
         of a material fact contained in any such registration statement,
         prospectus, offering circular or other document made by such Holder, or
         any omission (or alleged omission) to state therein a material fact
         required to be stated therein or necessary to make the statements by
         such Holder therein not misleading, and will reimburse the Company and
         such Other Stockholders, directors, officers, partners, persons,
         underwriters or control persons for any legal or any other expenses
         reasonably incurred in connection with investigating or defending any
         such claim, loss, damage, liability or action, in each case to the
         extent, but only to the extent, that such untrue statement (or alleged
         untrue statement) or omission (or alleged omission) is made in such
         registration statement, prospectus, offering circular or other document
         in reliance upon and in conformity with written information furnished
         to the Company by such Holder and stated to be specifically for use
         therein; provided, however, that the obligations of each of the Holders
         hereunder shall be limited to an amount equal to the net proceeds to
         such Holder of securities sold as contemplated herein.

                  (iii) Each party entitled to indemnification under this
         Section 2(f) (the "Indemnified Party") shall give notice to the party
         required to provide indemnification (the "Indemnifying Party") promptly
         after such Indemnified Party has actual knowledge of any claim as to
         which indemnity may be sought, and shall permit the Indemnifying Party
         to assume the defense of any such claim or any litigation resulting
         therefrom; provided that counsel for the Indemnifying Party, who shall
         conduct the defense of such claim or any litigation resulting
         therefrom, shall be approved by the Indemnified Party (whose approval
         shall not unreasonably be withheld) and the Indemnified Party may
         participate in such defense at such party's expense (unless the
         Indemnified Party shall have reasonably concluded that there may be a
         conflict of interest between the Indemnifying Party and the Indemnified
         Party in such action, in which case the fees and expenses of counsel
         shall be at the expense of the Indemnifying Party), and provided
         further that the failure of any Indemnified Party to give notice as
         provided herein shall not relieve the Indemnifying Party of its
         obligations under this Section 2 unless the

                                       -10-
<PAGE>

         Indemnifying Party is materially prejudiced thereby. No Indemnifying
         Party, in the defense of any such claim or litigation shall,
         except with the consent of each Indemnified Party, consent to
         entry of any judgment or enter into any settlement which does not
         include as an unconditional term thereof the giving by the claimant or
         plaintiff to such Indemnified Party of a release from all liability in
         respect to such claim or litigation. No Indemnified Party may settle or
         agree to settle any claim or litigation as to which indemnification may
         be sought hereunder without the prior written consent of the
         Indemnifying Party. Each Indemnified Party shall furnish such
         information regarding itself or the claim in question as an
         Indemnifying Party may reasonably request in writing and as shall be
         reasonably required in connection with the defense of such claim and
         litigation resulting therefrom.

                  (iv) If the indemnification provided for in this Section 2(f)
         is held by a court of competent jurisdiction to be unavailable to an
         Indemnified Party with respect to any loss, liability, claim, damage or
         expense referred to herein, then the Indemnifying Party, in lieu of
         indemnifying such Indemnified Party hereunder, shall contribute to the
         amount paid or payable by such Indemnified Party as a result of such
         loss, liability, claim, damage or expense in such proportion as is
         appropriate to reflect the relative fault of the Indemnifying Party on
         the one hand and of the Indemnified Party on the other in connection
         with the statements or omissions which resulted in such loss,
         liability, claim, damage or expense, as well as any other relevant
         equitable considerations. The relative fault of the Indemnifying Party
         and of the Indemnified Party shall be determined by reference to, among
         other things, whether the untrue (or alleged untrue) statement of a
         material fact or the omission (or alleged omission) to state a material
         fact relates to information supplied by the Indemnifying Party or by
         the Indemnified Party and the parties' relative intent, knowledge,
         access to information and opportunity to correct or prevent such
         statement or omission.

                  (v) Notwithstanding the foregoing, to the extent that the
         provisions on indemnification and contribution contained in the
         underwriting agreement entered into in connection with any underwritten
         public offering contemplated by this Agreement are in conflict with the
         foregoing provisions, the provisions in such underwriting agreement
         shall be controlling.

                  (vi) The foregoing indemnity agreement of the Company and
         Holders is subject to the condition that, insofar as they relate to any
         loss, claim, liability or damage arising out of a statement made in or
         omitted from a preliminary prospectus but eliminated or remedied in the
         amended prospectus on file with the Commission at the time the
         registration statement in question becomes effective or the amended
         prospectus filed with the Commission pursuant to Commission Rule 424(b)
         (the "Final Prospectus"), such indemnity or contribution agreement
         shall not inure to the benefit of any underwriter or Holder if a copy
         of the Final Prospectus was furnished to the underwriter or Holder and
         was not furnished to the person asserting the loss, liability, claim or
         damage at or prior to the time such action is required by the
         Securities Act.

                  (h) INFORMATION BY THE HOLDERS.

                                       -11-
<PAGE>

                  (i) Each of the Holders holding securities included in any
         registration shall furnish to the Company such information regarding
         such Holder and the distribution proposed by such Holder as the Company
         may reasonably request in writing and as shall be reasonably required
         in connection with any registration, qualification or compliance
         referred to in this Section 2.

                  (ii) In the event that, either immediately prior to or
         subsequent to the effectiveness of any registration statement, any
         Holder shall distribute Registrable Securities to its partners, such
         Holder shall so advise the Company and provide such information as
         shall be necessary to permit an amendment to such registration
         statement to provide information with respect to such partners, as
         selling securityholders. Promptly following receipt of such
         information, the Company shall file an appropriate amendment to such
         registration statement reflecting the information so provided. Any
         incremental expense to the Company resulting from such amendment shall
         be borne by such Holder. Any Holder who shall have effected such a
         distribution shall indemnify the Company in accordance with Section
         2(g) with respect to the information so provided to the Company.

                  (i) RULE 144 REPORTING.

                  With a view to making available the benefits of certain rules
and regulations of the Commission which may permit the sale of restricted
securities to the public without registration, the Company agrees to:

                  (i) make and keep public information available as those terms
         are understood and defined in Rule 144 under the Securities Act ("Rule
         144"), at all times;

                  (ii) use its best efforts to file with the Commission in a
         timely manner all reports and other documents required of the Company
         under the Securities Act and the Exchange Act; and

                  (iii) so long as the Holder owns any Registrable Securities,
         furnish to the Holder upon request, a written statement by the Company
         as to its compliance with the reporting requirements of Rule 144, and
         of the Securities Act and the Exchange Act, a copy of the most recent
         annual or quarterly report of the Company, and such other reports and
         documents so filed as the Holder may reasonably request in availing
         itself of any rule or regulation of the Commission allowing the Holder
         to sell any such securities without registration.

                  (j) TERMINATION. The registration rights set forth in this
         Section 2 shall not be available to any Holder if, (i) in the opinion
         of counsel to the Company, all of the Registrable Securities then owned
         by such Holder could be sold in any 90-day period pursuant to Rule 144
         or (ii) all of the Registrable Securities held by such Holder have been
         sold in a registration pursuant to the Securities Act or pursuant to
         Rule 144.

                                      -12-
<PAGE>

                  SECTION 3. MISCELLANEOUS

                  (a) DIRECTLY OR INDIRECTLY. Where any provision in this
Agreement refers to action to be taken by any Person, or which such Person is
prohibited from taking, such provision shall be applicable whether such action
is taken directly or indirectly by such Person.

                  (b) GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware applicable to
contracts made and to be performed entirely within such State.

                  (c) SECTION HEADINGS. The headings of the sections and
subsections of this Agreement are inserted for convenience only and shall not be
deemed to constitute a part thereof.

                  (d) NOTICES.

                  (i) All communications under this Agreement shall be in
         writing and shall be delivered by hand or facsimile or mailed by
         overnight courier or by registered or certified mail, postage prepaid,
         return receipt requested:

                  (1) if to the Company, to Daniel E. Geffken, Vice
         President-Finance and Chief Financial Officer, Transkaryotic Therapies,
         Inc., 195 Albany Street, Cambridge, MA 02139 (facsimile: (617)
         491-7903) or at such other address as it may have furnished in writing
         to the Holders with a copy to David E. Redlick, Esq., Hale and Dorr
         LLP, 60 State Street, Boston, Ma 02109 (facsimile: (617) 526-5000);

                  (2) if to the Holders, at the address or facsimile number
         listed on Schedule I hereto, or at such other address or facsimile
         number as may have been furnished the Company in writing.

                  (ii) Any notice so addressed shall be deemed to be given: if
         delivered by hand or facsimile, on the date of such delivery; if sent
         by overnight courier, on the first business day following the date of
         such sending; and if mailed by registered or certified mail, on the
         third business day after the date of such mailing.

                  (e) REPRODUCTION OF DOCUMENTS. This Agreement and all
documents relating thereto, including, without limitation, any consents, waivers
and modifications which may hereafter be executed may be reproduced by the
Holders by any photographic, photostatic, microfilm, microcard, miniature
photographic or other similar process and the Holders may destroy any original
document so reproduced. The parties hereto agree and stipulate that any such
reproduction shall be admissible in evidence as the original itself in any
judicial or administrative proceeding (whether or not the original is in
existence and whether or not such reproduction was made by the Holders in the
regular course of business) and that any enlargement, facsimile or further
reproduction of such reproduction shall likewise be admissible in evidence.

                                       -13-
<PAGE>

                  (f) SUCCESSORS AND ASSIGNS. This Agreement shall inure to the
benefit of and be binding upon the successors and assigns of each of the
parties.

                  (g) ENTIRE AGREEMENT; AMENDMENT AND WAIVER. This Agreement
constitutes the entire understanding of the parties hereto and supersedes all
prior understanding among such parties. This Agreement may be amended, and the
observance of any term of this Agreement may be waived, with (and only with) the
written consent of the Company and the Holders holding a majority of the then
outstanding Registrable Securities.

                  (h) SEVERABILITY. In the event that any part or parts of this
Agreement shall be held illegal or unenforceable by any court or administrative
body of competent jurisdiction, such determination shall not affect the
remaining provisions of this Agreement which shall remain in full force and
effect.

                  (i) COUNTERPARTS. This Agreement may be executed in one or
more counterparts, each of which shall be deemed an original and all of which
together shall be considered one and the same agreement.

                                       -14-
<PAGE>

                                      IN WITNESS WHEREOF, the undersigned have
executed this Agreement as of the date first set forth above.

                                               TRANSKARYOTIC THERAPIES, INC.

                                               By: /s/ DANIEL E. GEFFKEN
                                                   ------------------------
                                                   Name: Daniel E. Geffken
                                                   Title: VP of Finance and CFO

WARBURG, PINCUS EQUITY PARTNERS, L.P.

By:  WARBURG, PINCUS & CO.,
General Partner

By: /s/ JONATHAN LEFF
   --------------------
Name: Jonathan Leff
Title: Partner

WARBURG, PINCUS NETHERLANDS EQUITY PARTNERS I, C.V.

By:  WARBURG, PINCUS & CO.,
General Partner

By: /s/ JONATHAN LEFF
   --------------------
Name: Jonathan Leff
Title: Partner

WARBURG, PINCUS NETHERLANDS EQUITY PARTNERS II, C.V.

By:  WARBURG, PINCUS & CO.,
General Partner

By: /s/ JONATHAN LEFF
   ---------------------
Name: Jonathan Leff
Title: Partner

WARBURG, PINCUS NETHERLANDS EQUITY PARTNERS III, C.V.

By:  WARBURG, PINCUS & CO.,
General Partner

By: /s/ JONATHAN LEFF
   ---------------------
Name: Jonathan Leff
Title: Partner

                                       -15-
<PAGE>

                                   SCHEDULE I

                                    INVESTORS

                  INVESTOR NAME AND ADDRESS

Warburg, Pincus Equity Partners, L.P.
466 Lexington Avenue
New York, NY 10017
Facsimile: (212) 878-9351
Attention: Jonathan Leff

Warburg, Pincus Netherlands Equity Partners I, C.V.
466 Lexington Avenue
New York, NY 10017
Facsimile: (212) 878-9351
Attention: Jonathan Leff

Warburg, Pincus Netherlands Equity Partners II, C.V.
466 Lexington Avenue
New York, NY 10017
Facsimile: (212) 878-9351
Attention: Jonathan Leff

Warburg, Pincus Netherlands Equity Partners III, C.V.
466 Lexington Avenue
New York, NY 10017
Facsimile: (212) 878-9351
Attention: Jonathan Leff

                                       -16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]